Department of Pediatric Surgery, Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, Kagoshima, Japan.
Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, School of Medical and Dental Sciences, Kagoshima University Graduate, Kagoshima, Japan.
J Pediatr Surg. 2024 Apr;59(4):627-633. doi: 10.1016/j.jpedsurg.2023.11.028. Epub 2023 Dec 9.
We evaluated the effect of recombinant human hepatocyte growth factor (rh-HGF) on intestinal adaptation in a rat model of short-bowel syndrome (SBS).
Sprague-Dawley rats underwent jugular vein catheterization for continuous total parenteral nutrition (TPN) and 90 % small bowel resection. The animals were divided into 3 groups: TPN/SBS (control group, n = 7), TPN/SBS/intravenous recombinant human hepatocyte growth factor (HGF) (0.3 mg/kg/day) (HGF group, n = 7), and TPN/SBS/intravenous c-Met inhibitor (0.3 mg/kg/day) (anti-HGF group, n = 5). On day 7, rats were euthanized and histologically evaluated. Serum diamine oxidase (S-DAO) levels were evaluated using an enzyme-linked immunosorbent assay. The nutrient transporter and glucagon-like peptide-2 (GLP-2) receptor expression were evaluated using real-time polymerase chain reaction.
The jejunal and ileal villus heights were higher and the S-DAO concentrations significantly higher (p = 0.04) in the HGF group than in the control and anti-HGF groups. The sodium-dependent glucose transporter 1 expression in the HGF group was significantly higher than in the control group and significantly suppressed in the anti-HGF group (p < 0.01). The peptide transporter 1 expression in the jejunum was higher in the HGF group than in the other groups and significantly suppressed in the anti-HGF group (p < 0.01). The GLP-2 receptor expression in the jejunum was higher in the HGF group than the other groups, and it was significantly suppressed in the anti-HGF group (p < 0.01). These jejunal results regarding nutrient transporter an GLP-2 receptor were not found in the ileum.
The administration of rh-HGF appears to be more effective in the jejunum than in the ileum.
Experimental Research.
N/A.
我们评估了重组人肝细胞生长因子（rh-HGF）对短肠综合征（SBS）大鼠模型中肠道适应的影响。
Sprague-Dawley 大鼠行颈内静脉置管行全胃肠外营养（TPN）和 90%小肠切除术。动物分为 3 组：TPN/SBS（对照组，n=7）、TPN/SBS/静脉内重组人肝细胞生长因子（rh-HGF）（0.3mg/kg/天）（HGF 组，n=7）和 TPN/SBS/静脉内 c-Met 抑制剂（0.3mg/kg/天）（抗-HGF 组，n=5）。第 7 天处死大鼠并进行组织学评估。采用酶联免疫吸附试验（ELISA）检测血清二胺氧化酶（S-DAO）水平。采用实时聚合酶链反应（PCR）评估营养转运体和胰高血糖素样肽-2（GLP-2）受体的表达。
HGF 组空肠和回肠绒毛高度较高，S-DAO 浓度显著高于对照组和抗-HGF 组（p=0.04）。HGF 组钠依赖性葡萄糖转运体 1 表达明显高于对照组，抗-HGF 组明显抑制（p<0.01）。HGF 组空肠肽转运体 1 表达高于其他组，抗-HGF 组明显抑制（p<0.01）。HGF 组空肠 GLP-2 受体表达高于其他组，抗-HGF 组明显抑制（p<0.01）。这些空肠营养转运体和 GLP-2 受体的结果在回肠中并未发现。
rh-HGF 的给药在空肠中比回肠中更有效。
实验研究。
N/A。
